Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.80 USD
Change Today -2.22 / -22.16%
Volume 16.6M
EXAS On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

exact sciences corp (EXAS) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/25/15 - $32.85
52 Week Low
10/8/15 - $7.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EXACT SCIENCES CORP (EXAS)

exact sciences corp (EXAS) Related Bloomberg News

View More Bloomberg News

exact sciences corp (EXAS) Related Businessweek News

No Related Businessweek News Found

exact sciences corp (EXAS) Details

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company’s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with MAYO Foundation for Medical Education and Research for developing tests to detect other gastrointestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

236 Employees
Last Reported Date: 02/27/15
Founded in 1995

exact sciences corp (EXAS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $861.1K
Principal Financial Officer and Senior Vice P...
Total Annual Compensation: $383.1K
Chief Operating Officer, Senior Vice Presiden...
Total Annual Compensation: $638.6K
Chief Science Officer and Senior Vice Preside...
Total Annual Compensation: $518.4K
Compensation as of Fiscal Year 2014.

exact sciences corp (EXAS) Key Developments

Exact Sciences Corporation - Special Call

To discuss the U.S. Preventive Services Task Force release of its draft recommendations regarding colorectal cancer screening

Exact Sciences Corp. Announces Blue Cross Blue Shield of Rhode Island to Cover Cologuard®

Exact Sciences Corp. announced that it has entered into an agreement with Blue Cross Blue Shield of Rhode Island to include Cologuard under its Commercial and Medicare Advantage plans. The agreement will go into effect on September 15, 2015. Cologuard is the first and only FDA approved noninvasive stool-based DNA screening test for colon cancer. The test will be available to BCBS of Rhode Island members through their physician without a co-payment or co-insurance.

Exact Sciences Corporation Presents at Baird 2015 Healthcare Conference, Sep-09-2015 09:40 AM

Exact Sciences Corporation Presents at Baird 2015 Healthcare Conference, Sep-09-2015 09:40 AM. Venue: The New York Palace, 455 Madison Avenue, New York, New York, United States. Speakers: Kevin T. Conroy, Chairman of the Board, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXAS:US $7.80 USD -2.22

EXAS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.64 USD +0.01
Curis Inc $2.00 USD +0.03
Navidea Biopharmaceuticals Inc $2.26 USD -0.05
Veracyte Inc $6.40 USD +0.10
ZIOPHARM Oncology Inc $10.60 USD +0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation EXAS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 64.1x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 53.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXACT SCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at